Comparative Pharmacology
Head-to-head clinical analysis: CHIBROXIN versus MAXAQUIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHIBROXIN versus MAXAQUIN.
CHIBROXIN vs MAXAQUIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chibroxin (norfloxacin) is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
Fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
1-2 drops of 0.3% ophthalmic solution into affected eye(s) every 2 hours while awake for the first 2 days, then every 4 hours for 5-7 days.
400 mg orally once daily for 5-10 days; for complicated urinary tract infections, 400 mg orally once daily for 10-14 days.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours in adults with normal renal function. Prolonged to 12-24 hours in moderate renal impairment (CrCl 30-50 mL/min) and >24 hours in severe impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 12 hours (range 10-14 hours), supporting twice-daily dosing for systemic infections.
Renal: 98% as unchanged drug; hepatic: 2% as minor metabolites. Biliary/fecal excretion negligible.
Renal excretion of unchanged drug accounts for 70-80%; biliary/fecal elimination accounts for 20-30%.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic